What is the latest MEDPLUS stock price?
The latest stored price for MEDPLUS is Rs 595.25 as of 2026-11-03.
gimli
MEDPLUS stock AI analysis
MEDPLUS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MEDPLUS HEALTH SERV LTD is a small-cap stock in Consumer Services. This Gimli page shows the latest available MEDPLUS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹595.25
1W return
-4.22%
1M return
-9.02%
3M return
-14.52%
6M return
-31.75%
1Y return
-27.41%
Market cap
₹7,143.20 cr
PE
33.94
PB
3.62
ROE
+11.33%
ROCE
+9.37%
RSI
38.23
Turnover
₹1.88 cr
Why it can matter in screens
- Momentum: MEDPLUS is below 50DMA, below 200DMA; RSI is 38.23.
- Returns: 1D -0.21%, 1W -4.22%, 1M -9.02%, 3M -14.52%, 1Y -27.41%.
- Trend levels: 52W high ₹909.35, 52W low ₹565.60, off high -34.54%.
- Liquidity: latest turnover is ₹1.88 cr; volume vs 20D is +0.25%.
- Valuation/profitability: PE 33.94, PB 3.62, ROE +11.33%, ROCE +9.37%.
- Growth: 3Y sales CAGR +15.02%, 3Y profit CAGR +64.02%.
Quick Answers
Is MEDPLUS above its 50DMA and 200DMA?
MEDPLUS is below 50DMA, below 200DMA. The latest 50DMA is 643.28 and the latest 200DMA is 780.16.
What are MEDPLUS PE, ROE and ROCE?
MEDPLUS has PE 33.94, ROE +11.33%, and ROCE +9.37% in Gimli's latest available snapshot.
How has MEDPLUS performed recently?
MEDPLUS has returned -9.02% over 1 month, -14.52% over 3 months, and -27.41% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 1,879.60 cr | 153.07 cr | 33.18 cr | 2.76 |
| 2026-03-31 | 1,864.38 cr | 189.77 cr | 63.98 cr | 5.33 |
| 2025-12-31 | 1,806.12 cr | 176.86 cr | 57.81 cr | 4.82 |
| 2025-09-30 | 1,697.00 cr | 166.31 cr | 55.50 cr | 4.63 |
| 2025-06-30 | 1,542.63 cr | 145.75 cr | 42.36 cr | 3.54 |
| 2025-03-31 | 1,509.61 cr | 152.17 cr | 51.34 cr | 4.32 |
| 2024-12-31 | 1,561.45 cr | 145.04 cr | 45.89 cr | 3.84 |
| 2024-09-30 | 1,576.17 cr | 136.03 cr | 38.74 cr | 3.24 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 6,892.47 cr | 678.69 cr | 219.65 cr | 18.33 |
| 2025-03-31 | 6,136.05 cr | 535.72 cr | 150.32 cr | 12.57 |
| 2024-03-31 | 5,573.54 cr | 394.09 cr | 65.47 cr | 5.48 |
| 2023-03-31 | 4,528.68 cr | 312.23 cr | 49.76 cr | 4.17 |
| 2022-03-31 | 155.26 cr | 303.73 cr | 5.58 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,932.53 cr | 198.41 cr | 1,424.38 cr | 1,974.65 cr |
| 2025-03-31 | 3,360.09 cr | 86.05 cr | 1,119.80 cr | 1,739.90 cr |
| 2024-03-31 | 3,004.80 cr | 91.21 cr | 1,009.57 cr | 1,577.36 cr |
| 2023-03-31 | 2,796.72 cr | 228.38 cr | 899.92 cr | 1,490.50 cr |
| 2022-03-31 | 2,594.05 cr | 21.45 cr | 814.93 cr | 1,417.25 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 495.58 cr | 372.55 cr | n/a |
| 2025-03-31 | 540.43 cr | 480.98 cr | n/a |
| 2024-03-31 | 143.74 cr | 59.34 cr | n/a |
| 2023-03-31 | 90.41 cr | -78.60 cr | n/a |
| 2022-03-31 | 169.89 cr | 52.17 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +40.19% | +14.38% | +29.95% | +24.51% | +15.44% | +60.74% |
| 2026-03-31 | +40.22% | +15.53% | +27.82% | +22.60% | +16.40% | +60.74% |
| 2025-12-31 | +40.29% | +16.83% | +26.57% | +21.48% | +16.26% | +60.74% |
| 2025-09-30 | +40.29% | +16.54% | +26.52% | +21.48% | +16.61% | +59.34% |
| 2025-06-30 | +40.32% | +16.42% | +26.04% | +21.47% | +17.18% | +59.34% |
| 2025-03-31 | +40.34% | +15.61% | +26.19% | +21.59% | +17.82% | +59.34% |
| 2024-12-31 | +40.39% | +15.23% | +25.65% | +21.51% | +18.69% | +55.20% |
| 2024-09-30 | +40.39% | +14.72% | +27.97% | +18.08% | +16.85% | +54.17% |
| 2024-06-30 | +40.39% | +14.85% | +22.17% | +12.25% | +22.52% | +54.17% |
| 2024-03-31 | +40.39% | +14.94% | +22.47% | +12.87% | +22.10% | +54.17% |
| 2023-12-31 | +40.45% | +12.96% | +25.19% | +15.40% | +21.31% | +58.05% |
| 2023-09-30 | +40.41% | +12.36% | +25.49% | +15.60% | +21.62% | +50.53% |
| 2023-06-30 | +40.43% | +4.86% | +28.14% | +12.41% | +26.42% | +50.53% |
| 2023-03-31 | +40.43% | +4.49% | +28.16% | +12.21% | +26.73% | +50.53% |
| 2022-12-31 | +40.43% | +3.95% | +28.77% | +11.94% | +26.56% | +50.53% |
| 2022-09-30 | +40.43% | +3.74% | +28.84% | +12.17% | +26.64% | +50.53% |
| 2022-06-30 | +40.43% | +0.00% | +32.63% | n/a | n/a | +26.91% |
| 2022-03-31 | +40.43% | +0.00% | +32.21% | n/a | n/a | +26.91% |
| 2021-12-31 | +40.43% | +0.00% | +31.14% | n/a | n/a | +26.91% |
| 2021-12-22 | +40.43% | +0.00% | +14.85% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| ETERNAL | ETERNAL LIMITED | 321,280.56 cr | 651.684712 | +1.61% | +8.32% |
| DMART | AVENUE SUPERMARTS LIMITED | 219,061.82 cr | 70.286689 | +13.58% | -19.18% |
| INDHOTEL | THE INDIAN HOTELS CO. LTD | 119,006.05 cr | 53.837198 | +16.16% | +11.90% |
| LENSKART | LENSKART SOLUTIONS LTD | 116,033.64 cr | 176.718922 | +8.72% | n/a |
| TRENT | TRENT LTD | 107,943.78 cr | 59.253446 | +28.71% | -3.37% |
| MEESHO | MEESHO LIMITED | 102,254.21 cr | -85.125301 | -41.19% | n/a |
| NYKAA | FSN E COMMERCE VENTURES | 101,339.54 cr | 395.610340 | +18.01% | +41.51% |
| NAUKRI | INFO EDGE (I) LTD | 76,433.01 cr | 54.618808 | +3.63% | -13.21% |
Try these prompts
- Analyze MEDPLUS HEALTH SERV with valuation, momentum and industry peers
- Compare MEDPLUS with other Consumer Services stocks
- Show small-cap stocks in Consumer Services above 50DMA with positive 1M return
- Find Consumer Services stocks with improving momentum and reasonable valuation
Related screen ideas
- View Consumer Services stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare MEDPLUS with other Consumer Services stocks
Data snapshot: 2026-11-03. Not investment advice.